MA33691B1 - Schema posologique d'un modulateur des récepteurs de s1p - Google Patents

Schema posologique d'un modulateur des récepteurs de s1p

Info

Publication number
MA33691B1
MA33691B1 MA34805A MA34805A MA33691B1 MA 33691 B1 MA33691 B1 MA 33691B1 MA 34805 A MA34805 A MA 34805A MA 34805 A MA34805 A MA 34805A MA 33691 B1 MA33691 B1 MA 33691B1
Authority
MA
Morocco
Prior art keywords
receptor modulator
dosage scheme
dosage
scheme
sphingosine
Prior art date
Application number
MA34805A
Other languages
Arabic (ar)
English (en)
Inventor
Craig Boulton
Pascale Burtin
Olivier David
Vera Ana De
Thomas Dumortier
Irene Hunt
Robert Schmouder
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43759693&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA33691(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA33691B1 publication Critical patent/MA33691B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/02—Detecting, measuring or recording pulse, heart rate, blood pressure or blood flow; Combined pulse/heart-rate/blood pressure determination; Evaluating a cardiovascular condition not otherwise provided for, e.g. using combinations of techniques provided for in this group with electrocardiography or electroauscultation; Heart catheters for measuring blood pressure
    • A61B5/021—Measuring pressure in heart or blood vessels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/02—Detecting, measuring or recording pulse, heart rate, blood pressure or blood flow; Combined pulse/heart-rate/blood pressure determination; Evaluating a cardiovascular condition not otherwise provided for, e.g. using combinations of techniques provided for in this group with electrocardiography or electroauscultation; Heart catheters for measuring blood pressure
    • A61B5/024—Detecting, measuring or recording pulse rate or heart rate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/24—Detecting, measuring or recording bioelectric or biomagnetic signals of the body or parts thereof
    • A61B5/316—Modalities, i.e. specific diagnostic methods
    • A61B5/318—Heart-related electrical modalities, e.g. electrocardiography [ECG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/44—Detecting, measuring or recording for evaluating the integumentary system, e.g. skin, hair or nails
    • A61B5/441—Skin evaluation, e.g. for skin disorder diagnosis
    • A61B5/444—Evaluating skin marks, e.g. mole, nevi, tumour, scar
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/48—Other medical applications
    • A61B5/4833—Assessment of subject's compliance to treatment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483—Physical analysis of biological material
    • G01N33/487—Physical analysis of biological material of liquid biological material
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
    • G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H40/00—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices
    • G16H40/60—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices
    • G16H40/63—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for local operation
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/70—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H70/00—ICT specially adapted for the handling or processing of medical references
    • G16H70/40—ICT specially adapted for the handling or processing of medical references relating to drugs, e.g. their side effects or intended usage

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Medical Informatics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Primary Health Care (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Surgery (AREA)
  • Data Mining & Analysis (AREA)
  • Databases & Information Systems (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Physiology (AREA)
  • Analytical Chemistry (AREA)
  • Hematology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)

Abstract

Dans cette invention, des modulateurs des récepteurs de sphingosine-1-phosphate (s1p) sont administrés selon un schéma posologique qui assure un rapport bénéfice/risque positif.
MA34805A 2009-09-29 2012-04-26 Schema posologique d'un modulateur des récepteurs de s1p MA33691B1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US24670609P 2009-09-29 2009-09-29
US25832909P 2009-11-05 2009-11-05
US30799210P 2010-02-25 2010-02-25
US35202910P 2010-06-07 2010-06-07
PCT/US2010/049441 WO2011041146A2 (fr) 2009-09-29 2010-09-20 Schéma posologique d'un modulateur des récepteurs de s1p

Publications (1)

Publication Number Publication Date
MA33691B1 true MA33691B1 (fr) 2012-10-01

Family

ID=43759693

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34805A MA33691B1 (fr) 2009-09-29 2012-04-26 Schema posologique d'un modulateur des récepteurs de s1p

Country Status (18)

Country Link
US (8) US20120264719A1 (fr)
EP (4) EP3047848A1 (fr)
JP (5) JP2013505983A (fr)
KR (1) KR20120083442A (fr)
CN (2) CN102548579A (fr)
AU (2) AU2010300919A1 (fr)
BR (1) BR112012006957A2 (fr)
CA (2) CA2773330C (fr)
IL (2) IL218486A0 (fr)
MA (1) MA33691B1 (fr)
MX (1) MX2012003740A (fr)
NZ (1) NZ598534A (fr)
PH (1) PH12017501495A1 (fr)
RU (1) RU2012117563A (fr)
SG (4) SG10201902152XA (fr)
TN (1) TN2012000104A1 (fr)
WO (1) WO2011041146A2 (fr)
ZA (2) ZA201201678B (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2773330C (fr) * 2009-09-29 2021-11-02 Novartis Ag Schema posologique d'un modulateur des recepteurs de s1p
US20110124605A1 (en) * 2009-11-20 2011-05-26 Shreeram Aradhye Use of an S1P Receptor Agonist
CA2823616C (fr) 2011-01-07 2019-01-29 Novartis Ag Formulations d'immunosuppresseurs
JP6133790B2 (ja) * 2011-02-18 2017-05-24 ザ スクリプス リサーチ インスティテュート ミエリン形成細胞運命へのオリゴデンドロサイト前駆細胞の定方向分化
CA2851525A1 (fr) * 2011-10-12 2013-04-18 Teva Pharmaceutical Industries Ltd. Traitement de la sclerose en plaques par combinaison de laquinimod et de fingolimod
SG10201602279PA (en) * 2011-10-21 2016-04-28 Novartis Ag Dosage regimen for an s1p receptor modulator or agonist
CA3149287A1 (fr) * 2013-04-04 2014-10-09 Novartis Ag Identification de la reponse d'un patient a une administration d'un modulateur de recepteur de s1p
SG11201607894RA (en) * 2014-04-10 2016-10-28 Novartis Ag S1p modulator immediate release dosage regimen
CA2973540A1 (fr) 2015-02-26 2016-09-01 Novartis Ag Traitement de maladie auto-immune chez un patient recevant en outre un betabloquant
JP2022529474A (ja) * 2019-04-17 2022-06-22 ペア セラピューティクス （ユーエス）、インコーポレイテッド デジタル療法を利用する抑鬱症状、抑鬱障害の処置のための電子デバイスおよび方法
WO2021158844A1 (fr) * 2020-02-07 2021-08-12 Argentum Pharmaceuticals Llc Traitement et régime posologique pour modulateur du récepteur s1p
WO2021158839A1 (fr) * 2020-02-07 2021-08-12 Argentum Pharmaceuticals Llc Traitement et régime de dosage pour modulateur du récepteur s1p
WO2021158838A1 (fr) 2020-02-07 2021-08-12 Argentum Pharmaceuticals Llc Régime posologique d'un modulateur du récepteur s1p
WO2021158847A1 (fr) * 2020-02-07 2021-08-12 Argentum Pharmaceuticals Llc Traitement et régime posologique pour modulateur du récepteur s1p
WO2021158845A1 (fr) * 2020-02-07 2021-08-12 Argentum Pharmaceuticals Llc Traitement et régime posologique pour modulateur du récepteur s1p
WO2021158843A1 (fr) * 2020-02-07 2021-08-12 Argentum Pharmaceuticals Llc Traitement et régime posologique pour modulateur du récepteur s1p
WO2021158841A1 (fr) * 2020-02-07 2021-08-12 Argentum Pharmaceuticals Llc Traitement et régime pposologique pour modulateur du récepteur s1p
WO2024026089A2 (fr) * 2022-07-28 2024-02-01 Viewmind, Inc. Procédé d'identification d'altérations spécifiques chez des sujets ayant des maladies définies analysant des motifs oculomoteurs lors de l'utilisation de stimuli visuels spécifiques, un médicament ou un traitement spécifiques améliorant le traitement visuel, les performances cognitives et les activités cérébrales associées

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6231560B1 (en) * 1999-02-10 2001-05-15 Baxter International Inc Method and apparatus for automatically controlling the level of medication
GB0211261D0 (en) * 2002-05-16 2002-06-26 Novartis Ag Organic compounds
SI1505959T1 (sl) 2002-05-16 2009-04-30 Novartis Ag Uporaba vezavnih sredstev EDG receptorjev pri raku
PT1603544E (pt) * 2003-03-14 2008-01-22 Agi Therapeutics Res Ltd Tratamento de problemas intestinais com n-2,3,3-tetrametilbiciclo 2.2.2. heptan-2-amina
BRPI0410746A (pt) 2003-05-19 2006-06-27 Irm Llc compostos e composições imunossupressoras
US20050090520A1 (en) 2003-09-12 2005-04-28 Per Lindquist Treatment of disease or injury of the nervous system with FTY720
US7127355B2 (en) * 2004-03-05 2006-10-24 Perlegen Sciences, Inc. Methods for genetic analysis
EP1819326B1 (fr) 2004-11-29 2014-07-02 Novartis AG Posologie d'un agoniste du recepteur s1p
JP2007061274A (ja) * 2005-08-30 2007-03-15 Transcutaneous Technologies Inc センサからの副作用情報による投薬停止システムを備えたイオントフォレーシス装置
EP1923058A1 (fr) 2006-09-26 2008-05-21 Novartis AG Composition pharmaceutique enrobée comprenant un agoniste ou un modulateur de S1P
EP1905434A1 (fr) 2006-09-26 2008-04-02 Novartis AG Compositions organiques comprenant d'un agoniste de S1P recepteur et leur utilisation therapeutique
KR20180017232A (ko) 2008-06-20 2018-02-20 노파르티스 아게 다발성 경화증을 치료하기 위한 소아용 조성물
EP2907511A1 (fr) 2008-12-22 2015-08-19 Novartis AG Régime posologique pour un agoniste du récepteur s1p
CA2773330C (fr) * 2009-09-29 2021-11-02 Novartis Ag Schema posologique d'un modulateur des recepteurs de s1p

Also Published As

Publication number Publication date
AU2010101513A6 (en) 2014-07-10
EP3047848A1 (fr) 2016-07-27
SG178987A1 (en) 2012-04-27
AU2010300919A1 (en) 2012-03-22
RU2012117563A (ru) 2013-11-10
US20200222338A1 (en) 2020-07-16
TN2012000104A1 (en) 2013-09-19
CA3129729A1 (fr) 2011-04-07
US20160256416A1 (en) 2016-09-08
IL218486A0 (en) 2012-04-30
US20230086687A1 (en) 2023-03-23
NZ598534A (en) 2014-03-28
US20180263929A1 (en) 2018-09-20
JP2023093482A (ja) 2023-07-04
IL250439A0 (en) 2017-03-30
MX2012003740A (es) 2012-04-30
EP3061449A1 (fr) 2016-08-31
US20140187516A1 (en) 2014-07-03
WO2011041146A2 (fr) 2011-04-07
JP2020203892A (ja) 2020-12-24
CA2773330A1 (fr) 2011-04-07
US10543179B2 (en) 2020-01-28
US20170304226A1 (en) 2017-10-26
JP7185426B2 (ja) 2022-12-07
AU2010101513B4 (en) 2016-05-05
SG10201902152XA (en) 2019-04-29
RU2018118645A3 (fr) 2021-09-13
BR112012006957A2 (pt) 2016-06-14
EP2482810A2 (fr) 2012-08-08
US20180263930A1 (en) 2018-09-20
JP2013505983A (ja) 2013-02-21
ZA201404270B (en) 2014-12-23
WO2011041146A3 (fr) 2011-06-03
JP2018172401A (ja) 2018-11-08
CN103933570A (zh) 2014-07-23
CN102548579A (zh) 2012-07-04
ZA201201678B (en) 2016-01-27
JP2016155840A (ja) 2016-09-01
AU2010101513A4 (en) 2014-06-26
RU2018118645A (ru) 2018-11-05
SG10201913361RA (en) 2020-03-30
US20120264719A1 (en) 2012-10-18
PH12017501495A1 (en) 2018-07-02
EP3831371A1 (fr) 2021-06-09
CA2773330C (fr) 2021-11-02
SG10201406168RA (en) 2014-11-27
KR20120083442A (ko) 2012-07-25
US11759436B2 (en) 2023-09-19

Similar Documents

Publication Publication Date Title
MA33691B1 (fr) Schema posologique d'un modulateur des récepteurs de s1p
EA201100978A1 (ru) Схема приема агониста рецептора s1p
TN2011000281A1 (en) Dosage regimen of an s1p receptor agonist
EA021377B9 (ru) Модуляторы толл-подобных рецепторов
CR20110142S (es) Manguito quirúrgico
MA32703B1 (fr) Combinaison d'une insuline et d'un agoniste de glp 1
BRPI0514316A (pt) métodos e composições para modulação de atividade de receptor de esfingosina-1-fosfato (s1p)
IN2012DN02984A (fr)
BR112012028136A2 (pt) terapia de combinaçao
TW200621254A (en) Method for the treatment of attention deficit hyperactivity disorder
GB2464245A (en) Managing risk associated with various transactions
MX353550B (es) Uso de moleculas de enlace a semaforina-4d para la modulacion de la permeabilidad de la barrera sangre-cerebro.
EA201591404A1 (ru) Спиролактамные модуляторы рецептора nmda и их применение
UY31622A1 (es) Antagonistas de aminoalquilbifenilo n,n-disubstituidos de receptores de prostaglandina d2
MX2007010752A (es) Usos oftalmicos de moduladores de receptor s1p.
MX354818B (es) Moduladores del receptor x del higado.
MX354820B (es) Moduladores del receptor x del higado.
FR2939776B1 (fr) Bague de fixation et distributeur comprenant une telle bague.
BR112015033069A2 (pt) moduladores de receptor do hormônio de crescimento
BR112012006955A2 (pt) agente de acabamento mate ou fosco para vernizes de uv
MX2009011943A (es) Uso de modulador de los receptores de la sip.
MX2012011382A (es) Nuevo polimero.
MX2010002301A (es) Bomba para liquidos.
FR2968995B1 (fr) Composition pharmaceutioue pour une administration par voie orale destinee a eviter le mesusage
EA201001731A1 (ru) Применение радиоактивно меченой молекулы, которая специфически связывается с ed-b фибронектином, в способе лечения лимфомы ходжкина